Pharmacotherapy of iron overload in thalassaemic patients

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 10, 2003, Pages 1763-1774

  Ceci, Adriana ^a,b   Felisi, Mariagrazia ^b   De Sanctis, Vincenzo ^c   De Mattia, Domenico ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Div Ped   (Italy)

Author keywords

Chelating agents; Deferiprone; Deferoxamine; Iron overload; Thalassaemia

Indexed keywords

CYTOCHROME; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; HEMOSIDERIN; IRON; IRON CHELATING AGENT; MYOGLOBIN; TRANSFERRIN;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTHRALGIA; ARTHROPATHY; BINDING AFFINITY; BLOOD TRANSFUSION; BONE DISEASE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ERYTHEMA; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; INCREASED APPETITE; IRON OVERLOAD; LIVER DYSFUNCTION; LIVER TOXICITY; MOLECULAR WEIGHT; MUSCLE STIFFNESS; MYALGIA; NAUSEA; NEUTROPENIA; REVIEW; STEADY STATE; THALASSEMIA MAJOR; VISUAL IMPAIRMENT; VOMITING; YERSINIA ENTEROCOLITICA; YERSINIOSIS; ZINC DEFICIENCY;

BLOOD TRANSFUSION; CLINICAL TRIALS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; THALASSEMIA; TREATMENT OUTCOME;

EID: 0142210231     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.10.1763     Document Type: Review

References (69)

1. DE SANCTIS V, WONKE B: The management of homozygous beta-thalassaemia. In: Growth and endocrine complications in thalassemia. Medprint (1998):7-14.
2. CAPPELLINI N, COHEN A, ELEFTHERIOU A, PIGA A, PORTER J: Blood transfusion therapy in β-thalassemia major. In: Guidelines for the clinical management of thalassemia. Thalassaemia International Federation (2000):9-14.
3. ENGLE MA, ERLANDSON M, SMITH CH: Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation (1964) 30:698-705.
4. ZURLO MG, DE STEFANO P, BORGNA-PIGNATTI C et al.: Survival and causes of death in thalassaemia major. Lancet (1989) 2:27-30.
5. BRITTENHAM GM, GRIFFITH PM, NIENHUIS AW et al.: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. (1994) 331(9):567-573.
6. KATTAMIS CA, KATTAMIS AC: Management of thalassemias: growth and development, hormone substitution, vitamin, supplementation, and vaccination. Semin. Hematol. (1995) 36:269-275.
7. OLIVIERI NF, NATHAN DG, MACMILLAN JH et al.: Survival in medically treated patients with homozygous beta-thalassaemia. N. Engl. J. Med. (1994) 331(9):574-578.
8. BORGNA-PIGNATTI C, RUGOLOTTO S, DE STEFANO P et al.: Survival and disease complications in thalassemia major. Ann. NY Acad. Sci. (1998) 850:227-231.
9. GIARDINIA PJ, GRADY RW: Chelation therapy in β-thalassemia: an optimistic update. Semin. Hematol. (2001) 38(4):360-366.
10. KONTOGHIORGHES GJ, PATICCHI K, HADJIGAVRIEL M et al.: Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus. Sci. (2000) 23(3):211-223.
11. PONKA P, RICHARDSON DR, EDWARD JT et al.: Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro. Can. J. Physiol. Pharmacol. (1994) 72(6):659-666.
12. KONTOGHIORGHES GJ: New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review. Analyst (1995) 120(3):845-851.
13. KONTOGHIORGHES GJ: Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Arch. Toxicol. Suppl. (1996) 18:202-214.
14. HERSHKO C, KONIJN AM, LINK G: Iron chelators for thalassaemia. Br. J. Haematol. (1998) 101(3):399-406.
15. RICHARDSON DR, PONKA P: Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am. J. Hematol. (1998) 58(4):299-305.
16. COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS (COMP): Public Summary of positive opinion for orphan designation of 4-(3,5-bis-(hydroxyphenyl)-1,2,4)triazole-1-yl)-benzoic acid for the treatment of chronic iron overload requiring chelation therapy. EMEA/COMP/50/02 Rev. 1, London, UK, 8 January (2003).
17. HOFFBRAND AV, AL-REFAIE FN, DAVIS B et al.: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood (1998) 91(1):295-300.
18. TAHER A, CHAMOUN FM, KOUSSA S et al.: Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol. (1999) 101:173-177.
19. CECI A, BAIARDI P, FELISI M et al.: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br. J. Haematol. (2002) 118(1):330-336.
20. COHEN AR, GALANELLO R, PIGA A, DIPALMA A, VULLO C, TRICTA F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br. J. Haematol. (2000) 108:305-312.
21. MAZZA P, AMURRI B, LAZZARI G et al.: Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica (1998) 83(6):496-501.
22. TÖNDURY P, ZIMMERMANN A, NIELSEN P, HIRT A: Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br. J. Haematol. (1998) 101(3):413-415.
23. MAGGIO A, D'AMICO G, MORABITO A et al.: Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol. Dis. (2002) 28(2):196-208.
24. AL-REFAIE FN, WONKE B, HOFFBRAND AV, WICKENS DG, NORTEY P, KONTOGHIORGHES GJ: Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood (1992) 80(3):593-599.
25. AL-REFAIE FN, HOFFBRAND AV: Oral iron-chelating therapy: the L1 experience. Baillières Clin. Haematol. (1994) 7(4):941-963.
26. AL-REFAIE FN, HERSHKO C, HOFFBRAND AV et al.: Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br. J. Haematol. (1995) 91:224-229.
27. TAHER A, SHEIKH-TAHA M, KOUSSA S, INATI A, NEEMAN R, MOURAD F: Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur. J. Haematol. (2001) 67(1):30-34.
28. OLIVIERI NF, BRITTENHAM GM, MCLAREN CE et al.: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N. Engl. J. Med. (1998) 339(7):417-423.
29. ROMBOS Y, TZANETEA R, KONSTANTOPOULOS K et al.: Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica (2000) 85(2):115-117.
30. DEL VECCHIO GC, CROLLO E, SCHETTINI F, SCHETTINI F, FISCHER R, DE MATTIA D: Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematol. (2000) 104(2-3):99-102.
31. KUSHNER JP, PORTER JP, OLIVIERI NF: Secondary iron overload. Hematology (2001):47-61.
32. BRITTENHAM GM, BADMAN DG: Noninvasive measurement of iron: report of an NIDDK workshop. Blood (2003) 101(1):15-19.
33. ANDERSON LJ, HOLDEN S, DAVIS B et al.: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. (2001) 22(23):2171-2179.
34. CHABEREK S, MARTELL AE: Organic Sequestering Agents. John Wiley & Sons, Inc. New York, USA (1969).
35. HIDER RC, CHOUDHURY R, RAI BL, DEHKORDI LS, SINGH S: Design of orally active iron chelators. Acta Haematol. (1996) 95(1):6-12.
36. PORTER JB: Evaluation of new iron chelators for clinical use. Acta Haematol. (1996) 95(1):13-25.
37. Novartis Pharma AG: Desferal® (Desferrioxamine) Basic Prescribing Information. Novartis Pharma AG, Switzerland (1998).
38. PORTER JB, JASWON MS, HUEHNS ER, EAST CA, HAZELL JW: Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. (1989) 73(3):403-409.
39. BARMAN-BALFOUR JA, FOSTER RH: Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs (1999) 58:553-578.
40. PORTER JB: A risk-benefit assessment of iron-chelation therapy. Drug Saf. (1997) 17(6):407-421.
41. OLIVIERI NF, BRITTENHAM GM, ARMSTRONG SAM et al.: First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine. Blood (1995) 86(10 Suppl. 1):249a.
42. OLIVIERI NF, BRITTENHAM GM: Final Results of the Randomized Trial of Deferiprone and Deferoxamine. ASH Meeting (1997).
43. ANDERSON LJ, WONKE B, PRESCOTT E, HOLDEN S, WALKER JM, PENNELL DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemics. Lancet (2002) 360:516-520.
44. KOWDLEY KV, KAPLAN MM: Iron-chelation therapy with oral deferiprone - toxicity or lack of efficacy? N. Engl. J. Med. (1998) 339(7):468-469.
45. ALDOURI MA, WONKE B, HOFFBRAND AV et al.: Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine J. Clin. Pathol. (1987) 40:1353-1359.
46. MAURER HS, LLOYD-STILL JD, INGRISANO C, GONZALEZ-CRUSSI F, HONIG GR: A prospective evaluation of iron chelation therapy in children with severe β-thalassemia. A six-year study. Am. J. Dis. Child. (1988) 142:287-292.
47. BERDOUKAS V, BOHANE T, EAGLE C et al.: The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfus. Sci. (2000) 23(3):239-240.
48. CALLEA F. Iron chelation with oral deferiprone in patients with thalassemia. N. Engl. J. Med. (1998) 339(23):1710-1711.
49. WANLESS I, SWEENEY G, DHILLON AP et al.: Lack of progressive hepatic fibrosis during long term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood(2002) 100(5):1566-1569.
50. AGARWAL MB, GUPTE SS, VISWANATHAN C et al.: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br. J. Haematol. (1992) 82:460-466.
51. OLIVIERI NF, BRITTENHAM GM, MATSUI D et al.: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N. Engl. J. Med. (1995) 332(14):918-922.
52. BASRAN RK, FASSOS FF, SHAW D, OLIVIERI NF: Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood (1994) 84(No. 10 Suppl. 1):261a.
53. ZAHED L, MOURAD FH, ALAMEDDINE R, AOUN S, KOUSSA S, TAHER A: Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia (2002) 31(4):333-339.
54. LESIC B, FOULON J, CARNIEL E: Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia entercolitica. Antimicrob. Agents Chemother. (2002) 46(6):1741-1745.
55. CHERCHI GB, PACIFICO L, COSSELLU S et al.: Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr. Infect. Dis. J. (1995) 14:579-584.
56. CHERCHI GB, COSSELLU S, PACIFICO L et al.: Incidence and outcome of Yersinia enterocolitica infection in thalassemic patients. Contrib. Microbiol. Immunol. (1995) 13:16-18.
57. CAPPELL MS, SIMON T: Colonic toxicity of administered medications and chemicals. Am. J. Gastroenterol. (1993) 88:1684-1699.
58. GRADY RW, GIARDINIA PJ: Iron chelation: rationale for combination therapy. In: Iron chelators: new development strategies. Badman DG, Bergeron RJ, Brittenham GM (Eds), The Saratoga Group, Ponte Vedra, FL, USA (2000):293-310.
59. BREUER W, ERMERS MJ, POOTRAKUL P, ABRAMOV A, HERSHKO C, CABANTCHIK ZI: Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood (2001) 97(3):792-798.
60. WONKE B, WRIGHT C, HOFFBRAND AV: Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol. (1998) 103(2):361-364.
61. AYDINOK Y, NISLI G, KAVAKLI K, COKER C, KANTAR M, CETINGUL N: Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematol. (1999) 102(1):17-21.
62. BALVEER K, PYAR K, WONKE B: Combined oral and parenteral iron chelation in beta thalassaemia major. Med. J. Malaysia (2000) 55(4):493-497.
63. MOURAD FH, HOFFBRAND AV, SHEIKH-TAHA M, KOUSSA S, KHORIATY AI, TAHER A: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. (2003) 121(1):187-189.
64. FARMAKI K, ANAGNOSTOPOULOS G, PLATIS O, GOTSIS E, TOULAS P: Combined chelation therapy in patients with thalassaemia major: a fast and effective method of reducing ferritin & cardiological complications. European Haematology Conference (2002).
65. ALYMARA V, BOURANTAS DK, CHAIDOS A et al.: Combined iron chelation therapy with desferrioxamine and deferiprone in β-thalassemic patients. European Haematology Conference (2002).
66. KATTAMIS A, KASSOU CH, LADIS V, BERDUSSI H, APOSTOLAKOU F, KATTAMIS C: Combination therapy with desferrioxamine and deferiprone in thalassemic patients. 12th International Conference on Oral Chelation in the Treatment of Thalassemia & Other Diseases (ICOC). Santorini, Greece (2002):105.
67. BANSAL RK: Combined chelation with desferrioxamine and deferiprone in thalassemia major. 12th International Conference on Oral Chelation in the Treatment of Thalassemia & Other Diseases (ICOC). Santorini, Greece (2002):120.
68. TAHER A, MOURAD FH, KOUSSA S, INATI A, HOFFBRAND AV: Effect of desferrioxamine, deferiprone or a combination therapy in iron overload thalassemia patients: the Lebanese experience. 12th International Conference on Oral Chelation in the Treatment of Thalassemia & Other Diseases (ICOC). Santorini, Greece (2002):120.
69. MODELL B, KHAN M, DARLISON M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet (2000) 355(9220):2051-2052.